Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Avila Therapeutics has received new patent no. 7,982,036, '4,6-Disubstituted Pyrimidines Useful as Kinase Inhibitors,' from the US Patent and Trademark Office (USPTO).
Subscribe to our email newsletter
The new patent covers compositions of matter for a particular class of targeted covalent drugs that selectively and irreversibly inhibit kinases such as members of the epidermal growth factor receptor (EGFR) family (including EGFR and Her2) and the Tec kinase family (including Bruton’s Tyrosine Kinase (Btk)), which were designed and tested by the company using its proprietary Avilomics platform.
Avila is developing its own therapeutic programs based on this platform and has leveraged its intellectual property assets through alliances with Sanofi, Clovis Oncology, and the Novartis Option Fund.
Avila founder and chief scientific officer Juswinder Singh said the Avilomics platform offers an approach to the design and development of targeted covalent drugs.
"We’re creating portfolio of intellectual property to capture protection for large categories of chemical structures in this emerging class of medicines, as well as for the insights we use to produce them," Singh said.